<u>Products</u> / <u>Stents: Coronary</u> / SYNERGY™

# **SYNERGY**<sup>TM</sup>

#### Monorail

#### **Everolimus-Eluting Platinum Chromium Coronary Stent System**

Exceptional Deliverability SYNERGY™ 48 mm

Clinical Outcomes











The SYNERGY™ BP Stent features an innovative delivery system for Exceptional Deliverability.

# Zero in on Safety. Heal With Confidence.

The SYNERGY™ Bioabsorbable Polymer Stent comes with Synchrony bioabsorbable polymer coating on the abluminal side. Polymer is gone when no longer needed, shortly after completion of drug elution at 3 months. Providing Suppression of neointimal growth at the arterial wall & Promotion of healing inside the lumen.

The SYNERGY™ Stent System is equipped with a delivery system having new Laser-cut hypotube technology which provides exceptional deliverability by improving pushability and trackability.


### **Explore**

**Exceptional Deliverability** SYNERGY™ 48 Mm **Early Healing** Clinical Outcomes Ordering Information

## **Exceptional Deliverability**

Synergy™ stent system comes with New laser-cut Hypotube technology having ~300 cuts over 100 mm length. It Extends into midshaft to exit port to improve pushability. Additional length maintains midshaft flexibility.


Laser-cut hypotube provides exceptional deliverability by improving pushability and trackability.



Read more >

# SYNERGY™ 48 mm

Long lesions represent a complex lesion subset that is associated with increased safety related events, reduced efficacy and increased procedure time.



Read more >







#### Abiummai bioabsorbable polymei (br.) application

Emphasizes suppression of neointimal growth at the arterial wall while promoting healing inside the vessel.

#### Thin, rounded struts

Stents with thinner strut designs have been shown to heal faster than thicker strut stents.<sup>1</sup>



#### Fast-absorbing bioabsorbable polymer

Polymer is gone when it is no longer needed, shortly after the drug is completely eluted.  $^{2}$ 

#### **Optimal drug release**

Market-leading Everolimusdrug is completely eluted with optimal kinetics at 3 months.

Read more >

### **Clinical Outcomes**

The SYNERGY™ BP Stent demonstrates consistently low stent thrombosis rates in over 18,000 patients across 9 studies


#### ARC ST (Def) Rates for the SYNERGY™ BP Stent<sup>17</sup>

Low late and very late ST rates across multiple trials.

	SWEET Registry	Fribourg Experience	Belfast Experience	EVOLVE II Trial	EVOLVE Trial	EVOLVE China Trial	EVOLVE II QCA Study	SCAAR Registry	BIO-RESORT Trial
N:	820	671	185	846	94	205	100	14,979§	1,172
Acute ≤ 1-day	1.5%	0.3%	0%	0.2%	0%	0%	0%	0.08%§	0.1%
Sub-acute 2-30-days	0.1%	0.3%	0%	0%	0%	0%	0%	0.02%§	0.1%
Late 30 days-1-year	0.1%	0.1%	0%	0%	0%	0%	0%	0.20%§	0.2%
Very Late Beyond 1-year			0%	0.2%	0%			0.10%5	0.3%

Read more >

#### **Ordering Information**



### SYNERGY™ BP Stent, now available in 48mm



		<u>Professionals</u>	<u>Patients</u>	<u>Products</u>	About		48	Overexpansion Capabilities
								3.50
)	H7493926220250	H7493926224250	7493926228250	H7493926232250	H7493926238250	H7493	3926248250	3.50
)	H7493926220270	H7493926224270	H749392622B270	H7493926232270	H7493926238270	H7493	3926248270	3.50
)	H7493926220300	H7493926224300	H7493926228300	H7493926232300	H7493926238300	H7493	3926248300	4.25
)	H7493926220350	H7493926224350	H74939?.6228350	H7493926232350	H7493926238350	H7493	3926248350	4.25
)	H7493926220400	H7493926224400	H7493926228400	H7493926232400	H7493926238400	H7493	3926248400	5.75
)	H7493926220450	H7493926224450	H7493926228450	H7493926232450				5.75
)	H7493926220500	H7493926224500	H7493926228500	H74939262J2500				5.75

# **Exceptional Deliverability**

SYNERGY™ 48 mm

**Early Healing** 

Learn about the continued advancement in deliverability that SYNERGY™ offers.

Discover the FIRST and ONLY 48 mm DES.

Find out how synchronous drug elution and polymer absorption enables early healing.







This page is restricted to be accessed by Healthcare Professionals only, Nothing on this website should be construed as the giving of advice or the making of a recommendation regarding any decision or action related to the professional decisions of the HCPs or influence their professional autonomy. If you are a patient, firstly, you should not access this page and secondly, you should consult a doctor or other qualified healthcare professional regarding any questions you have about your health or before making any treatment decisions. If you are a doctor or other qualified healthcare professional, you should not allow the contents of this website to substitute for your own medical judgment, which you should enter the newblating the information on this Website. Results from different studies are not offered; companishe, information provided for educational purposes only.

SYNERGY is a registered trademark of Boston Scientific Corporation or its affiliates. All other trademarks are the property of their respective owners.

Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.









INDH-IC-1041103AA-JUN21

©2023 Boston Scientific Corporation or its affiliates. All rights reserved. All trademarks are property of their respective owners.

Privacy Policy Terms of Use Copyright Notice

<sup>1.</sup> Soury N. Feygin | et al. EuroIntervention. 2010 Nov.6(5) 630-7.
2. Wilson S. J. et al. Cathleter Calcilovasc Interv.
17. SWEET Registry Cook 17 2015. | Interval Species Cook 17. 2016 | Belfast Experience: Noad TCT 2015, EVOLVE II: Kerelakes, et al. Circ Cardiovasc.